A 22% response rate was achieved in clinical trials of Russian drug cycloplatam in disseminated and hormone-resistant cancer of the prostate. In 80% of cases the drug has improved quality of life of patients with prostatic cancer stage III and IV. Antitumor effect and low toxicity make cycloplatam applicable in combined therapy of prostatic cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
prostatic cancer
8
[cycloplatam treatment
4
treatment patients
4
patients disseminated
4
disseminated prostatic
4
prostatic cancer]
4
cancer] 22%
4
22% response
4
response rate
4
rate achieved
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!